✦ LIBER ✦

A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer

✍ Scribed by Grothey, Axel

Book ID: 121224907
Publisher: Nature Publishing Group
Year: 2008
Tongue: English
Weight: 148 KB
Volume: 6
Category: Article
ISSN: 1743-4254
DOI: 10.1038/ncponc1261

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

XELOX vs FOLFOX-4 as first-line therapy

XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results

✍ Cassidy, J; Clarke, S; Díaz-Rubio, E; Scheithauer, W; Figer, A; Wong, R; Koski, 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 347 KB

Capecitabine plus oxaliplatin (XELOX) ve

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer

✍ Michel Ducreux; Jaafar Bennouna; Mohamed Hebbar; Marc Ychou; Gérard Lledo; Thier 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 440 KB

## Abstract A regimen consisting of 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) is widely used in France in the first‐line treatment of metastatic colorectal cancer (MCRC). The aim of our study was to demonstrate the non‐inferiority of capecitabine plus oxaliplatin (XELOX) __versus__ FOLF

FOLFOX Alternated with FOLFIRI as First-

FOLFOX Alternated with FOLFIRI as First-Line Chemotherapy for Metastatic Colorectal Cancer

✍ Jorge Aparicio; Carlos Fernández-Martos; Jose M. Vicent; Inmaculada Maestu; Chri 📂 Article 📅 2005 🏛 CIG Media Group, LP. 🌐 English ⚖ 121 KB

PCN87 PHARMACOECONOMIC ANALYSIS OF DIREC

PCN87 PHARMACOECONOMIC ANALYSIS OF DIRECT MEDICAL COSTS OF METASTATIC COLORECTAL CANCER THERAPY WITH XELOX OR FOLFOX4 WITH OR WITHOUT BEVACIZUMAB AS THE FIRST-LINE TREATMENT

✍ A Tikhomirova; A Kulikov; R Yagudina 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

Biweekly XELOX (capecitabine and oxalipl

Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer

✍ Grande, Carlos; Quintero, Guillermo; Candamio, Sonia; París Bouzas, Lorena; Vill 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 337 KB

Continuing Single-Agent Bevacizumab as M

Continuing Single-Agent Bevacizumab as Maintenance Therapy After Induction XELOX (or FOLFOX) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer

✍ Diaz-Rubio, E.; Pietrantonio, F.; de Braud, F. 📂 Article 📅 2012 🏛 Alphamed Press 🌐 English ⚖ 192 KB